RE: Total car crash of a share24 Jan 2025 09:50
NICE said:
1. "The committee stated a preference for laboratory-based tests over point-of-care tests. It noted that there was very little difference in the QALYs generated in the EAG's model by the different methods of testing."
2. "The committee had previously concluded that tests that detected fewer loss-of-function alleles would likely disproportionately affect certain ethnic groups (see section 3.8). While Genedrive detects more alleles than Genomadix, laboratory-based testing has the potential to detect an even broader range.
3. "Also, if needed, laboratory testing can be adapted more easily to assess other alleles in the future. Several stakeholders and experts also commented that centralised testing would reduce variability in testing offered across the NHS.
4."Experts raised concerns that if left to local centres to implement testing with point-of-care tests, this would likely lead to considerable variation and could worsen health inequalities."
5. "A stakeholder also commented that centres usings point-of-care tests would need to have quality-assurance processes in place and consider who is responsible for ensuring these.
6. "Some committee members stated that existing infrastructure should be preferentially used over investing in new single-purpose technologies.
7. "Experts also highlighted that, in the future, pharmacogenomic testing may be reactive when clopidogrel is needed, but pre‑emptive pharmacogenomic tests for other treatments could be done at the same time. This would require a panel of tests that would be more easily done in a laboratory."
https://www.nice.org.uk/guidance/dg59/chapter/3-Committee-discussion
Sign In
Follow the stocks
